Multicenter randomized clinical trials utilizing high volume urine tumor DNA analysis for urothelial cancer diagnosis, treatment, surveillance and screening
Bidragets beskrivning
This research project aims to validate and test an easy-to-use, accurate, and cost-effective urine test (UroScout) for detecting urothelial cancers of the bladder and upper urinary tract in clinical studies and randomized trials. By analyzing tumor DNA in urine, UroScout can help reduce the need for invasive diagnostic procedures like cystoscopies and ureteroscopies, as well as imaging studies. Urine samples can be collected at home and mailed for analysis, making testing more accessible. The project aims to enhance early cancer detection, optimize patient care, and improve healthcare cost-effectiveness. By advancing knowledge of tumor mutational profiles, the study also supports the development of precision medicine approaches, enabling the identification of diverse tumor types and facilitating targeted treatment strategies, ultimately increasing survival rates and quality of life.
Visa merStartår
2025
Slutår
2029
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Kliniska forskare
Beslutfattare
Forskningsrådet för biovetenskap, hälsa och miljö
16.06.2025
16.06.2025
Övriga uppgifter
Finansieringsbeslutets nummer
369661
Forskningsområden
Kliiniset lääketieteet